Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up

REFERENCES

• Hawkins BS, Bird A, Klein R, et al. Epidemiology of age-related macular degeneration. Mol Vis. 1999;5:26.
   Google Scholar
• Friedman DS, OColmain BJ, Mun˜oz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572.
   Google Scholar
• Lazreg S, Delcourt C, Zeggane S, et al. Age-related macular degeneration and its risk factors in North Africans living in Algeria and Italy. Ophthalmic Res. 2016;56:145–154.
   Google Scholar
• Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology. 2003;110:25–33.
   Google Scholar
• Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol. 1998;116:1646–1651.
   Google Scholar
• Kumaramanickavel G. Age-related macular degeneration: Genetics and biology. Asia Pac J Ophthalmol (Phila). 2016;5:229–235.
   PubMed Web of Science ®Google Scholar
• Tan PL, Bowes Rickman C, Katsanis N. AMD and the alternative complement pathway: Genetics and functional implications. Hum Genomics. 2016;10:23.
   PubMed Web of Science ®Google Scholar
• De Co´Rdoba SR, De Jorge EG. Translational mini-review series on complement factor H: Genetics and disease associations of human complement factor H. Clin Exp Immunol. 2008;151:1–13.
   PubMed Web of Science ®Google Scholar
• Scholl HP, Charbel Issa P, Walier M, et al. Systemic complement activation in age-related macular degeneration. Plos One. 2008;3:e2593.
   Google Scholar
• Hecker LA, Edwards AO, Ryu E, et al. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet. 2010;19:209–215.
   PubMed Web of Science ®Google Scholar
• Hao XF, Xie LK, Tang YZ, et al. Association of complement factor H gene polymorphisms with age-related macular degeneration susceptibility. Int J Clin Exp Pathol. 2015;8:3186–3191.
   Google Scholar
• Donoso LA, Vrabec T, Kuivaniemi H. The role of complement Factor H in age-related macular degeneration: A review. Surv Ophthalmol. 2010;55:227–246.
   PubMed Web of Science ®Google Scholar
• Challis RC, Araujo GS, Wong EK, et al. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2016;27:1617–1624.
   Google Scholar
• Janssen Van Doorn K, Dirinck E, Ga V, et al. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. Clin Kidney J. 2013;6:216–219.
   Google Scholar
• Gotoh N, Yamada R, Hiratani H, et al. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet. 2006;120:139–143.
   PubMed Web of Science ®Google Scholar
• Jabbarpoor Bonyadi MH, Yaseri M, Bonyadi M, et al. Association of combined complement factor H Y402H and ARMS/LOC387715 A69S polymorphisms with age-related macular degeneration: A meta-analysis. Curr Eye Res. 2016;7:1–7.
   Google Scholar
• Sepp T, Khan JC, Thurlby DA, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006;47:536–540.
   Google Scholar
• Loyet KM, Deforge LE, Katschke KJ Jr, et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:6628.
   Google Scholar
• Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in pa- tients with neovascular AMD. Invest Ophthalmol Vis Sci. 2011;52:4694–4702.
   Google Scholar
• McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol. 2012;96:208–212.
   Google Scholar
• Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2009;93:610–613.
   Google Scholar
• Kepez Yildiz B, Ozdek S, Ergun MA, et al. CFH Y402H and VEGF polymorphisms and anti-VEGF treatment response in exudative age-related macular degeneration. Ophthalmic Res. 2016;56:132–138.
   Google Scholar
• Dikmetas O, Kadayifcilar S, Eldem O. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab. Mol Vis. 2013;19:2571–2578.
   PubMed Web of Science ®Google Scholar
• Hagstrom SA, Ying GS, Pauer GJ, et al. Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013;120:593–599.
   Google Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385–389.
   Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419–421.
   Google Scholar
• Edwards AO. Ritter R 3rd, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421–424.
   Google Scholar
• Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227–7232.
   PubMed Web of Science ®Google Scholar
• Clark SJ, Bishop PN. Role of factor H and related proteins in regulating complement activation in the macula, and relevance to age-related macular degeneration. J Clin Med. 2015;4:18–31.
   PubMed Web of Science ®Google Scholar
• Brantley MA Jr, Am F, Jm K, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168–2173.
   Google Scholar
• Grunwald JE, Pistilli M, Daniel E, et al. Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104.
   Google Scholar